



COMPARISON
OF THE
WHO ATC CLASSIFICATION
&
***Eph*MRA/PBIRG ANATOMICAL**
CLASSIFICATION:

VERSION January 2011

Comparison of the WHO ATC Classification and *EphMRA* / PBIRG Anatomical Classification

The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. *EphMRA* and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence.

In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified.

WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C2A as antihypertensive agent, N2C as anti-migraine product and S1E as ophthalmic product).

EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only.

The purposes of classification are also different:

The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring.

This classification is recommended by the WHO for use in international drug utilisation research.

The *EphMRA*/PBIRG classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.

The aim of harmonisation is to reach a “full” agreement of all mono substances in a given class as listed in the WHO ATC Index (2011),

mainly at third level: whenever this is not possible, or harmonisation of third level is too difficult or makes no sense (e.g. C2, R3), the second level will be taken as the reference class.

Harmonisation is not a simple adaptation of two systems; harmonisation is clearly an improvement of the existing systems.

In view of the increasing use of the WHO classification by national and international authorities and institutions with different objectives, it is opportune to have a harmonised classification.

The main benefit is that all parties involved in a given topic, use the same definitions, same substances, and therefore the discussions are easier.

In line with the harmonisation procedure of WHO/*EphMRA*, this booklet has been prepared to facilitate cross-comparison.

The comparison has been based on the WHO guidelines. Whenever possible, we have checked all molecules included in the WHO/ATC Index 2011 with the *EphMRA* coding.

We have tried to simplify the document and for this reason and according to the pre-agreed mandate of harmonisation, only the 3rd level has been used as a point of reference.

However, in some cases (e.g. A2B1 antiulcer and group L) we have also mentioned the 4th levels in our comparison.

Where the two groups are similar, on the *EphMRA* side only the code and the title has been added.

Where a difference exists, this has been notified using the following symbols:

- ❖ This class/code does not exist (e.g. A3B)
- ↻ The heading or the content of this class may be different (e.g. N5C).
- These substances are classified in a different class.
- + This class is covered by more than one *EphMRA*/PBIRG class

A lot of discrepancies concern rather obsolete products for which there is no need for harmonisation (e.g. products withdrawn from the market, sales of minor importance).

We hope this booklet will improve both the use and understanding of the two systems, in particular for those companies in which the two systems are used by different departments (medical and marketing).

The Committee has tried to make a comprehensive comparison of both systems, but cannot guarantee a 100% level of accuracy.

For complete guidelines on the WHO ATC systems refer to “Guidelines for ATC classification, 2011” and for the *EphMRA*/PBIRG Anatomical classification system refer to “*EphMRA* / PBIRG classification 2011”.

To obtain the guidelines please contact:

Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology P.O. Box 4404 Nydalen N-0403 OSLO Fax: +47-23408146 email: whocc@fhi.no web: www.whocc.no	Bernadette Rogers Secretary of EPhMRA Minden House 351 Mottram Road Stalybridge, SK15 2SS Cheshire, UK Fax: +44 161 304 8104 Email: MrsBRogers@aol.com	Carol Reilly Executive Director, PBIRG 1758 Allentown Road, Box 209 Lansdale, PA 19446 USA Telephone: [1] 215 855 5255 Fax: [1] 215 855 5622 Email: creilly@pbirg.com .
---	---	--

WHO (Substance based)

EphMRA (Product based)

A ALIMENTARY TRACT AND METABOLISM

A01 STOMATOLOGICAL PREPARATIONS

A01A STOMATOLOGICAL PREPARATIONS

- Preparations for the treatment of **throat** infections (lozenges for common cold conditions) are classified in **R02** - Throat preparations
- Cevimeline is classified in N7A



A02 DRUGS FOR ACID RELATED DISORDERS

A02A ANTACIDS

- Plain antitflatulents, see A02BX

A02B DRUGS FOR PEPTIC ULCER and GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

A02B A H2-receptor antagonists

A02B B Prostaglandins

A02B C Proton pump inhibitors

A02B D Combinations for eradication of Helicobacter pylori

A02B X Other drugs for peptic ulcer and gastro-oesophageal disease (GORD)

A02X OTHER DRUGS FOR ACID RELATED DISORDERS

A ALIMENTARY TRACT AND METABOLISM

A1 STOMATOLOGICALS, MOUTH PREPARATIONS, MEDICINAL DENTIFRICES ETC.

A1A STOMATOLOGICALS

- Products indicated for both the **posterior part of the mouth and throat** infections are classified in **R2A or A1A depending on their main indication**
- +
- Cevimeline is classified here

A1B MOUTH ANTIFUNGALS

A2 ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS

A2A ANTACIDS, ANTIFLATULENTS, CARMINATIVES

- Plain antitflatulents are classified in this group

A2B ANTIULCERANTS

A2B1 H2 antagonists

A2B3 Prostaglandin antiulcerants

A2B2 Acid pump inhibitors

A2B4 Bismuth antiulcerants + A2B9 All other antiulcerants

A2C OTHER STOMACH DISORDER PREPARATIONS

WHO (Substance based)

EphMRA (Product based)

A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	A3	FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS
A03A	DRUGS FOR FUNCTIONAL BOWEL DISORDERS	A3A	PLAIN ANTISPASMODICS AND ANTICHOLINERGICS
	➤ Chlorbenzoxamine is classified here		➤ Chlorbenzoxamine is classified in A2B
	➤ Trimebutine is classified here		➤ Trimebutine is classified in A3F
+	➤ Alosetron and tegaserod are classified here (A3A E)		➤ Alosetron and tegaserod are classified in A3G
A03B	BELLADONNA AND DERIVATIVES, PLAIN	❖	
A03C	ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	A3C	ANTISPASMODIC/ATARACTIC COMBINATIONS
A03D	ANTISPASMODICS IN COMBINATION WITH ANALGESICS	A3D	ANTISPASMODIC/ANALGESIC COMBINATIONS
	➤ Combinations with both psycholeptics and analgesics are classified in A03E A		➤ Combination of both ataractic and analgesic are classified here
A03E	ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS		
A03E A	Antispasmodics, psycholeptics and analgesics in combination		
	➤ Antispasmodics in combination with psycholeptics, analgesics and other agents are classified in this group		➤ Combinations of both ataractics and analgesics are classified in A3D
A03E D	Antispasmodics in combination with other drugs	A3E	ANTISPASMODICS COMBINED WITH OTHER PRODUCTS
A03F	PROPULSIVES	A3F	GASTROPROKINETICS
	➤ Trimebutine is classified in A03A		Trimebutine is classified here
❖			

WHO (Substance based)

EphMRA (Product based)

A3AE DRUGS ACTING ON SEROTONIN RECEPTORS

A3G GASTRO-INTESTINAL SENSORIMOTOR MODULATORS

A04 ANTIEMETICS AND ANTINAUSEANTS

A4 ANTIEMETICS AND ANTINAUSEANTS

A04A ➤ ANTIEMETICS AND ANTINAUSEANTS

A4A ANTIEMETICS AND ANTINAUSEANTS

➤ Antihistamines are classified in R06A

➤ Antihistamines used in motion sickness are classified here

➤ Butaperazine is classified in N05A

A05 BILE AND LIVER THERAPY

A5 CHOLAGOGUES AND HEPATIC PROTECTORS

A05A BILE THERAPY

A5A BILE THERAPY AND CHOLAGOGUES

A05B LIVER THERAPY, LIPOTROPICS

A5B HEPATIC PROTECTORS, LIPOTROPICS

A05C DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION

A5C CHOLAGOGUE/LIPOTROPIC COMBINATIONS

A06 LAXATIVES

A6 LAXATIVES

A06A LAXATIVES

A6A LAXATIVES

A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY / ANTIINFECTIVE AGENTS

A7 ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTIINFLAMMATORIES

A07A INTESTINAL ANTIINFECTIVES

A7A INTESTINAL ANTIINFECTIVE ANTIDIARRHOEALS

A07B INTESTINAL ADSORBENTS

A7B INTESTINAL ABSORBANT ANTIDIARRHOEALS

➤ Albumin and ceratonia are classified in A07X

A07C ELECTROLYTES WITH CARBOHYDRATES

A7G ORAL ELECTROLYTE REPLACERS

A07D ANTIPROPULSIVES

A7H MOTILITY INHIBITORS

WHO (Substance based)

EphMRA (Product based)

A07E INTESTINAL ANTIINFLAMMATORY AGENTS

A7E INTESTINAL ANIINFLAMMATORY AGENTS

A07F ANTIDIARRHEAL MICROORGANISMS

A7F ANTIDIARRHOEAL MICRO-ORGANISMS

A07X OTHER ANTIDIARRHEALS

A7X ALL OTHER ANTIDIARRHOEALS

➤ Albumin tannate and ceratonia are classified here

➤ Albumin tannate and ceratonia are classified in A7B

A08 ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS

A8 ANTI OBESITY PREPARATIONS, EXCL. DIETETICS

A08A ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS

A8A ANTI OBESITY PREPARATIONS, EXCL. DIETETICS

➤ Amphetamine is classified in N06B

Amphetamine, when indicated as antiobesity product, is classified here

A09 DIGESTIVES, INCL. ENZYMES

A9 DIGETIVES, INCL. DIGESTIVE ENZYMES

A09A DIGESTIVES, INCL. ENZYMES

A9A DIGESTIVES, INCL. DIGESTIVE ENZYMES

A10 DRUGS USED IN DIABETES

A10 DRUGS USED IN DIABETES

A10A INSULINS and ANALOGUES

A10C HUMAN INSULINS and ANALOGUES

+

A10D ANIMAL INSULINS

A10B ORAL BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

➤ Guar gum is classified here

➤ Exenatide is classified here (A10BX)

A10H SULPHONYLUREA ANTIDIABETICS

A10J BIGUANIDE ANTIDIABETICS

A10J1 BIGUANIDE ANTIDIABETICS, PLAIN

A10J2 BIGUANIDE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS

A10J9 BIGUANIDE ANTIDIABETIC COMBINATIONS, OTHER

A10K GLITAZONE ANTIDIABETICS

A10K1 GLITAZONE ANTIDIABETICS, PLAIN

A10K2 GLITAZONE AND SULPHONYLUREA ANTIDIABETIC COMBINATIONS

A10K3 GLITAZONE AND BIGUANIDE ANTIDIABETIC COMBINATIONS

A10K9 GLITAZONE ANTIDIABETIC COMBINATIONS, OTHER

A10L ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS

A10M GLINIDE ANTIDIABETICS

A10M1 GLINIDE ANTIDIABETICS, PLAIN

A10M3 GLINIDE AND BIGUANIDE ANTIDIABETIC COMBINATIONS

WHO (Substance based)

EphMRA (Product based)

A10M9	GLINIDE ANTIDIABETIC COMBINATIONS, OTHER
A10N	DPP-IV INHIBITOR ANTIDIABETICS
A10N1	DPP-IV INHIBITOR ANTIDIABETICS, PLAIN
A10N3	DPP-IV INHIBITOR AND BIGUANIDE ANTIDIABETIC COMBINATIONS
A10N9	DPP-IV INHIBITOR ANTIDIABETIC COMBINATIONS, OTHER
A10S	GLP-1 AGONIST ANTIDIABETICS

A10X OTHER DRUGS USED IN DIABETES

Includes aldose reductase inhibitors

- Guar gum is classified in A10B
- Thiocotic acid is classified in A16A

A10X OTHER DRUGS USED IN DIABETES

A10X1 Antidiabetic multitherapy combination products, includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity.

A10X9 OTHER DRUGS USED IN DIABETES

- Guar gum is classified here
- Thiocotic acid is classified here or A16A

A11 VITAMINS

- Vitamin B₁₂ is classified in B03

A11 VITAMINS

Vitamin B₁₂ is classified in A11F, which is a code only used in the EphMRA/PBIRG system

A12 MINERAL SUPPLEMENTS

A12 MINERAL SUPPLEMENTS

A12A CALCIUM

A12A CALCIUM PRODUCTS

A12B POTASSIUM

A12B POTASSIUM PRODUCTS

A12C OTHER MINERAL SUPPLEMENTS

A12C OTHER MINERAL SUPPLEMENTS

WHO (Substance based)

EphMRA (Product based)

A13 TONICS

A13A TONICS

A13 TONICS

A13A TONICS

The large number of products in this class make it impossible to fully state that they are equal

A14 ANABOLIC AGENTS FOR SYSTEMIC USE

A14A ANABOLIC STEROIDS

A14B OTHER ANABOLIC AGENTS

A14 ANABOLICS, SYSTEMIC

A14A ANABOLIC HORMONES, SYSTEMIC

A14B OTHER ANABOLIC AGENTS, SYSTEMIC

A15 APPETITE STIMULANTS

- Cyproheptadine is classified in R06A
- Pizotifen is classified in N02C

A15 APPETITE STIMULANTS

- Cyproheptadine **when indicated as appetite stimulant, is classified here**, otherwise is classified in R6A
- Pizotifen is classified here; when indicated for migraine, is classified in N2C

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

- Includes levocarnitine, ademetionine, thioctic acid
- Zinc acetate is classified here

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

- Levocarnitine is classified here; when indicated for ischaemic disorders, is classified in C1X
- Ademetionine is classified in N6A
- Thioctic acid is classified here or in A10X
- Combinations of diabetes and cardiovascular products are classified in A10X1

WHO (Substance based)

EphMRA (Product based)

- Zinc acetate is classified in V3E when indicated for Wilson's disease

WHO (Substance based)

EphMRA (Product based)

B BLOOD AND BLOOD FORMING ORGANS

B01 ANTITHROMBOTIC AGENTS

B01A ANTITHROMBOTIC AGENTS



B01A A Vitamin K antagonists

B01A B Heparin group

- Antithrombin III is classified here
- Danaparoid is classified here

B01A C Platelet aggregation inhibitors excl. heparin

- Dipyridole is classified here
- Defibrotide is classified in B1A X

B01A D Enzymes



- Protein C and activated Protein C are classified here

B01A E Direct thrombin inhibitors

B01A X Other antithrombotic agents

- Defibrotide is classified here

B BLOOD AND BLOOD FORMING ORGANS

B1 ANTITHROMBOTIC AGENTS



B1A VITAMIN K ANTAGONISTS

B1B HEPARINS

- Antithrombin III is classified in B2C
- Danaparoid is classified in B1X

B1C PLATETLET AGGREGATION INHIBITORS

- Dipyridole is classified here; when indicated for coronary therapy it is classified in C1D
- Defibrotide is classified here

B1D FIBRINOLYTICS



- Protein C and activated Protein C are classified in B1X

B1E DIRECT THROMBIN INHIBITORS

B1X OTHER ANTITHROMBOTIC AGENTS

- Defibrotide is classified in B1C

WHO (Substance based)

EphMRA (Product based)

B02 ANTIHEMORRHAGICS

B02A ANTIFIBRINOLYTICS

B02A A Amino acids

B02A B Proteinase inhibitors

B02B VITAMIN K AND OTHER HEMOSTATICS

B02B A Vitamin K

➤ protamin is classified in VO3A

B02B B Fibrinogen

B02B C ➤ Local hemostatics

B02B D Blood coagulation factors

B02B X Other systemic hemostatics

➤ Romiplostim is classified here

B2 BLOOD COAGULATION SYSTEM, OTHER PRODUCTS

B2A ANTIFIBRINOLYTICS

B2A ANTIFIBRINOLYTICS

B2C PROTEINASE INHIBITORS

B2B ANTAGONISTS (ANTIDOTES TO ANTICOAGULANTS)

B2B1 Vitamin K

B2B2 Protamin is classified here

B2F TISSUE SEALING PREPARATIONS

➤ Local hemostatics are classified in D3A

B2D BLOOD COAGULATION

B2G SYSTEMIC HAEMOSTATICS

➤ Romiplostim is classified in B6C

B03 ANTIANEMIC PREPARATIONS

B03A IRON PREPARATIONS

➤ All plain iron preparations and all combination products containing more than 30 mg Fe per defined daily dose (DDD), are classified here, even if they contain multivitamins.

B3 ANTI-ANAEMIC PREPARATIONS

B3A HAEMATINICS, IRON & ALL COMBINATIONS

➤ Combinations of iron with multivitamins are classified in A11A.

B03B VITAMIN B12 AND FOLIC ACID

B3B LIVER EXTRACTS AND COMBINATIONS WITH B12



WHO (Substance based)

EphMRA (Product based)



B03B A Vitamin B12 (cyanocobalamin and analogues)

B03B B Folic acid and derivatives

➤ Folinic acid is classified in V03A

B03X OTHER ANTIANEMIC PREPARATIONS

B03X A Other antianemic preparations

A11F PLAIN VIT B12

B3X OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID

➤ Folinic acid with more than one indication classified in V3D

B3C ERYTHROPOIETIN PRODUCTS



B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

B05A BLOOD AND RELATED PRODUCTS

B05A A Blood substitutes and plasma protein fractions

B05B I.V. SOLUTIONS

B05B A Solutions for parenteral nutrition

+

B05B B Solutions affecting the electrolyte balance

➤ Trometamol is classified here

B05B C Solutions producing osmotic diuresis

B05C IRRIGATING SOLUTIONS



K HOSPITAL SOLUTIONS

K3B PROTEIN SOLUTIONS

+

K2 PLASMA EXPANDERS

K1 INTRAVENOUS SOLUTIONS

➤ Trometamol is classified in K4B

K1F SOLUTIONS FOR OSMOTIC THERAPY

K5 IRRIGATING SOLUTIONS

WHO (Substance based)

EphMRA (Product based)

B05D PERITONEAL DIALYTICS

K6B PERITONEAL DIALYSIS SOLUTIONS

B05X I.V. SOLUTION ADDITIVES

K4 INJECTION SOLUTIONS/INFUSION ADDITIVES

B05Z HEMODIALYTICS AND HEMOFILTRATES

B05Z A Hemodialytics, concentrates

K6A HAEMODIALYSIS SOLUTIONS

B05Z B Hemofiltrates

K6C HAEMOFILTRATION

B06 OTHER HEMATOLOGICAL AGENTS

B6 ALL OTHER HEMATOLOGICAL AGENTS

B06A OTHER HEMATOLOGICAL AGENTS

❖

B6B HYALURONIDASE

+

B6C OTHER HEMATOLOGICAL AGENTS

WHO (Substance based)

EphMRA (Product based)

C **CARDIOVASCULAR SYSTEM**

C01 CARDIAC THERAPY

C01A CARDIAC GLYCOSIDES

C01B ANTIARRHYTHMICS, CLASS I AND III

- Adenosine is classified in C01E

C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C01C A Adrenergic and dopaminergic agents

- Caffeine, plain is classified in N06B
- Heptaminol is classified in C01D
- Dihydroergotamine is classified in N02C

C01C E Phosphodiesterase Inhibitors



+

C01C X Other cardiac stimulants

C01D **VASODILATORS USED IN CARDIAC DISEASES**

C01D A Organic nitrates

- Amyl nitrite is classified in V03A

C01D B Quinolone vasodilators

C **CARDIOVASCULAR SYSTEM**

C1 CARDIAC THERAPY

C1A CARDIAC GLYCOSIDES AND COMBINATIONS

C1B ANTI-ARRHYTHMICS

- Adenosine is classified here

C1C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

C1C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

- Caffeine, plain is classified here
- Heptaminol is classified in this group
- Dihydroergotamine is classified here and in N2C

C1F POSITIVE INOTROPIC AGENTS

Includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol

C1E **NITRITES AND NITRATES**

- Amyl nitrite is classified here and V3A

WHO (Substance based)

EphMRA (Product based)

- C01D X Other Vasodilators used in cardiac diseases
- Prenylamine is classified here
 - Heptaminol is classified here
 - Dipyramidol is classified in B01AC
 - Trimetazidine is classified in C01E

- C1D CORONARY THERAPY EXCL. CALCIUM ANTAGONISTS AND NITRITES
- Prenylamine is classified in C8A
 - Heptaminol is classified in C1C
 - Dipyramidol is classified here and in B1C
 - Trimetazidine is classified here
 - Ivabradine is classified here

- C01E OTHER CARDIAC PREPARATIONS
- Adenosine is classified here
 - Levocarnitine is classified in A016
 - Trimetazidine is classified here
 - Ivabradine is classified here

- C1X ALL OTHER CARDIAC PREPARATIONS
- Adenosine is classified in C1B
 - Levocarnitine is classified in this group when indicated for ischaemic disorders (in A16 if for nutrition problems)
 - Ivabradine is classified C1D

- C02 ANTIHYPERTENSIVES**
- Mebutamate is classified in N05B
 - Terazosin is classified in G04C
 - Bosentan is classified here

- C2 ANTIHYPERTENSIVES**
- Mebutamate is classified in C2A
 - Terazosin is classified here and in G4C
 - Bosentan is classified in C6A

WHO (Substance based)

EphMRA (Product based)

C03 DIURETICS

- Cicletanine is classified here

C3 DIURETICS

- Cicletanine is classified in C2A

C04 PERIPHERAL VASODILATORS

C04A PERIPHERAL VASODILATORS

- Cinnarizine and flunarizine are classified in N07C
- Nimodipine is classified in C08
- Citicoline is classified in N06B
- Visnadine is classified here

C4 CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS

C4A CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS

- Cinnarizine and flunarizine can be classified here and also in N2C and N7C depending on indications
- Nimodipine is classified here
- Citicoline is classified here
- Visnadine is classified in C1D

C05 VASOPROTECTIVES

C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C5 ANTIVARICOSIS/ANTIHAEMORRHOIDAL PREPARATIONS

C5A TOPICAL ANTI-HAEMORRHOIDALS

WHO (Substance based)

EphMRA (Product based)

C05B ANTIVARICOSE THERAPY

C5B VARICOSE THERAPY, TOPICAL

C05C CAPILLARY STABILIZING AGENTS

C5C VARICOSE THERAPY, SYSTEMIC



- Bosentan is classified in C2K
- Iloprost is classified here or in B1A
- Sildenafil is classified in G4B

C6 OTHER CARDIOVASCULAR PRODUCTS

- Bosentan is classified here
- Iloprost is classified here or in B1C depending on indication
- Sildenafil is classified here or in G4E depending on indication

C07 **BETA BLOCKING AGENTS**

C7 **BETA BLOCKING AGENTS**

C07A BETA BLOCKING AGENTS

C7A BETA BLOCKING AGENTS, PLAIN

C07B BETA BLOCKING AGENTS AND THIAZIDES

C7B BETA BLOCKING AGENTS, COMBINATIONS

+

C07C BETA BLOCKING AGENTS AND OTHER DIURETICS

+

C07D BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS

+

C07E BETA BLOCKING AGENTS AND VASODILATORS

WHO (Substance based)

EphMRA (Product based)

C07F BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES

- Combinations with calcium channel blockers are classified here

- Combinations with calcium channel blockers are classified in C8B

C08 CALCIUM CHANNEL BLOCKERS

- Nimodipine is classified here
- Prenylamine is classified in C01D X
- Combinations with beta blockers are classified in C07F

C8 CALCIUM ANTAGONISTS

- Nimodipine is classified in C4A
- Prenylamine is classified here
- Combinations with beta blockers are classified in C8B2

C08C SELECTIVE CCB WITH MAINLY VASCULAR EFFECT

+

C08D SELECTIVE CCB WITH DIRECT CARDIAC EFFECTS

+

C08E NON-SELECTIVE CALCIUM CHANNEL BLOCKERS

C8A CALCIUM ANTAGONISTS, PLAIN

C8G CALCIUM CHANNEL BLOCKERS AND DIURETICS

C8B1 CALCIUM ANTAGONISTS COMBINATIONS WITH ANTIHYPERTENSIVES (C2) AND/OR DIURETICS



C8B2 CCB/BETABLOCKER COMBINATIONS

C8B3 CCB COMB. WITH OTHER DRUGS OF GROUP C, except C7-C10

C8B4 CCB COMBINATIONS WITH ALL OTHER DRUGS

WHO (Substance based)

EphMRA (Product based)

C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09A	ACE INHIBITORS, PLAIN
C09B	ACE INHIBITORS, COMBINATIONS
C09C	ANGIOTENSIN II ANTAGONISTS, PLAIN
C09D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
C09X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C9A	ACE INHIBITORS, PLAIN
C9B	ACE INHIBITORS, COMBINATIONS
C9C	ANGIOTENSIN II ANTAGONISTS, PLAIN
C9D	ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
C9X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C10	LIPID MODIFYING AGENTS
C10A	LIPID MODIFYING AGENTS, PLAIN
C10A A	HMG CoA reductase inhibitors
C10A B	Fibrates
C10A C	Bile acid sequestrants
C10A D	Nicotinic acid and derivatives
+	
C10A X	Other lipid modifying agents



C10	LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS
C10A	CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS
C10A 1	Statins (HMG-CoA reductase inhibitors)
C10A 2	Fibrates
C10A 3	Ion-exchange resins
C10A 9	All other cholesterol/triglyceride regulators
C10 B	ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN

WHO (Substance based)

EphMRA (Product based)

C10B LIPID MODIFYING AGENTS, COMBINATIONS

- Lipid-regulating cardiovascular multitherapy combination products are classified here

C10C LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS

- Lipid-regulating cardiovascular multitherapy combination products are classified in C11A



C11 CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS



- Lipid-regulating cardiovascular multitherapy combination products are classified in C10B

C11A LIPID-REGULATING CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

WHO (Substance based)

EphMRA (Product based)

D DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE

D01A ANTIFUNGALS FOR TOPICAL USE

- Topical metronidazole is mainly used for rosacea and is classified in D06B X
- Combinations with corticosteroids are classified here

D01B ANTIFUNGALS FOR SYSTEMIC USE

- Terbinafine is classified here

D02 EMOLLIENTS AND PROTECTIVES

D02A EMOLLIENTS AND PROTECTIVES

- + ➤ Aminobenzoic acid is classified in D02B

D02B PROTECTIVES AGAINST UV-RADIATION

- Betacarotene is classified here
 - Aminobenzoic acid is classified here
-

D DERMATOLOGICALS

D1 ANTIFUNGALS, DERMATOLOGICAL

D1A1 Topical dermatological antifungals

- Products indicated for the treatment of rosacea are classified in D10A
- Combinations with corticosteroids are in D7B2

D1A2 Systemic dermatological Antifungals

- Terbinafine is classified in J2A

D2 EMOLLIENTS, PROTECTIVES

D2A EMOLLIENTS, PROTECTIVES

- Aminobenzoic acid is classified here

- Betacarotene is classified in D11A
-

WHO (Substance based)

EphMRA (Product based)

D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS

D3 WOUND HEALING AGENTS

➤ Local haemostatics are classified in B02B C

➤ Local haemostatics are classified here

D03A CICATRIZANTS

❖

D03B ENZYMES

❖

D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.

D4 ANTIPRURITICS, INCL. TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC.

D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC

D4A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANAESTHETICS, ETC.

➤ Nalfurafine is classified in V3A

➤ Nalfurafine is classified here

D05 ANTIPSORIATICS

D5 NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

D05A ANTIPSORIATICS FOR TOPICAL USE

D5A TOPICAL ANTIPSORIASIS PRODUCTS

D05B ANTIPSORIATICS FOR SYSTEMIC USE

D5B SYSTEMIC ANTIPSORIASIS PRODUCTS

➤ Alefacept is classified in L4A

➤ Alefacept is classified here

➤ Methotrexate is classified in L01B and L04A

➤ Methotrexate is classified in D5B, M1C and L1B

➤ Ustekinumab is classified in L04A

➤ Ustekinumab is classified here

WHO (Substance based)

EphMRA (Product based)

❖		D5X	OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS
	➤ Topical tacrolimus is classified in D11A		➤ Topical tacrolimus is classified here
	➤ Alitretinoin is classified in D11A		➤ Alitretinoin is classified in here when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma

D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	D6	TOPICAL ANTIBACTERIALS AND ANTIVIRALS
	➤ Metronidazole for the treatment of rosacea is classified here		➤ Metronidazole for treatment of rosacea is classified in D10A
	➤ Dressings with antiinfectives are classified in D09A A		➤ Dressings with anti-infectives are classified here

D06A	ANTIBIOTICS FOR TOPICAL USE	D6A	TOPICAL ANTIBACTERIALS
------	-----------------------------	-----	------------------------

D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE	D6A	TOPICAL ANTIBACTERIALS
------	-----------------------------------	-----	------------------------

(- D6B B)			
D06B B	Antivirals	D6D	TOPICAL ANTIVIRALS INFECTION PRODUCTS

D6C	ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS	❖	Included in D6A
-----	---	---	-----------------

WHO (Substance based)

EphMRA (Product based)

D07 **CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS**

D07A CORTICOSTEROIDS, PLAIN

D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS

+

D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS

+

D07X CORTICOSTEROIDS, OTHER COMBINATIONS

D7 **TOPICAL CORTICOSTEROIDS**

D7A PLAIN TOPICAL CORTICOSTEROIDS

D7B TOPICAL CORTICOSTEROID COMBINATIONS

❖

❖

D08 **ANTISEPTICS AND DISINFECTANTS**

D08A ANTISEPTICS AND DISINFECTANTS

D8 **ANTISEPTICS AND DISINFECTANTS**

D8A ANTISEPTICS AND DISINFECTANTS

D09 **MEDICATED DRESSINGS**



D09A MEDICATED DRESSINGS

This group comprises medicated dressings, ointment dressings etc. Liquid wound protectives are classified in D02A D – Liquid plasters. Local hemostatics, eg. Gauze, tampons etc. are classified in B02B C – Local hemostatics.

D09A A Ointment dressings with antiinfectives

❖

THE PRODUCTS OF THIS CLASS HAVE BEEN ALLOCATED TO THE DIFFERENT GROUPS

Included
in
D6A

TOPICAL ANTIBIOTICS AND/OR SULPHONAMIDES

WHO (Substance based)

EphMRA (Product based)

D09A B Zinc bandages

Included
in
D5A

TOPICAL ANTIPSORIASIS AND SIMILAR PRODUCTS

D09A X Soft paraffin dressings

Included
in
D2A

EMOLLIENTS, PROTECTIVES

D10 ANTI-ACNE PREPARATIONS

D10 ANTI-ACNE PREPARATIONS

D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE

D10A TOPICAL ANTI-ACNE PREPARATIONS

- Metronidazole for the treatment of rosacea is classified in D06B

- Metronidazole for the treatment of rosacea is classified here

D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

D10B ORAL ANTI-ACNE PREPARATIONS

- Antibiotics, such as tetracyclines and erythromycin, which are also used for the treatment of acne are classified in group J
- Combinations of estrogen and antiandrogen, used for the treatment of acne, are classified in group G03 H

- Antibiotic products, specifically indicated for the treatment of acne are classified here.
 - Combinations of estrogen and cyproterone, specifically indicated for the treatment of acne, are classified here.
-
-

WHO (Substance based)

EphMRA (Product based)

D11 OTHER DERMATOLOGICAL PREPARATIONS

D11A OTHER DERMATOLOGICAL PREPARATIONS

- Androgens for topical use are classified here
- Tacrolimus and pimecrolimus are classified here
- Alitretinoin is classified here

D11 OTHER DERMATOLOGICAL PREPARATIONS

D11A OTHER DERMATOLOGICAL PREPARATIONS

- Androgens for topical use are in D3A
 - Tacrolimus is classified in D5X and L4A; pimecrolimus in D5X
 - Alitretinoin is classified in D5X when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma
-

WHO (Substance based)

EphMRA (Product based)

G GENITO URINARY SYSTEM AND SEX HORMONES

G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS

- All oral and rectal dosage forms of imidazole derivatives are classified in P01A

G GENITO-URINARY SYSTEM AND SEX HORMONES

G1 GYNAECOLOGICAL ANTI-INFECTIVES

- Dosage forms used for treatment of gynaecological infections are classified here

G02 OTHER GYNAECOLOGICALS

- Analgesics used in dysmenorrhea are classified in N02B

G2 OTHER GYNAECOLOGICALS

- Analgesics indicated exclusively for dysmenorrhea are classified in G2X1

G02A OXYTOCICS

- Oxytocin and demoxytocin are classified in H01B

G2A LABOUR INDUCERS

- Oxytocin and demoxytocin are classified here

G02B CONTRACEPTIVES FOR TOPICAL USE

- IUDs containing progestogens are classified here

G2B TOPICAL CONTRACEPTIVES

- IUDs with progestogens are classified in G3A

G02C OTHER GYNECOLOGICALS

- Vaginal forms of estrogens are classified in G03C

❖

- Vaginal forms of estrogens are classified in G2F

G02C A Sympathomimetics, labor repressants

G2E LABOUR INHIBITORS

❖

- Vaginal forms of estrogens are classified in G03C

G2F TOPICAL SEX HORMONES

- Vaginal forms of estrogens are classified here

WHO (Substance based)

EphMRA (Product based)

G02C B	Prolactin inhibitors <ul style="list-style-type: none">➤ Lisuride tablets in high strength (0.2mg) are classified in this group, while low dose tablets (25 mcg) are classified in N02C➤ Bromocriptine low dose is classified here; high strength tablets are classified in N04B➤ Cabergoline low dose is classified here, high strength tablets are classified in N04B
G02C C	Antiinflammatory products for vaginal administration
+	
G02C X	Other gynaecologicals

G2D	PROLACTIN INHIBITORS <ul style="list-style-type: none">➤ Lisuride is classified in N4A➤ Bromocriptine is classified here and N4A➤ Cabergoline is classified here and N4A
G2X	OTHER GYNAECOLOGICAL PRODUCTS

G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

G3 SEX HORMONES AND PRODUCTS WITH SIMILAR DESIRED EFFECTS, SYSTEMIC ACTION ONLY

G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE <ul style="list-style-type: none">➤ IUDs with progestogens are classified in G02B
------	--

G3A	HORMONAL CONTRACEPTIVES, SYSTEMIC <ul style="list-style-type: none">➤ IUDs with progestogens are classified here
-----	--

G03B	ANDROGENS
------	-----------

G3B	ANDROGENS, EXCLUDING G3E, G3F
-----	-------------------------------

G03C	ESTROGENS <ul style="list-style-type: none">➤ Tibolone is classified here➤ Vaginal forms are classified here
------	---

G3C	OESTROGENS, EXCLUDING G3A, G3E, G3F <ul style="list-style-type: none">➤ Tibolone is classified G3X➤ Vaginal forms are classified G2F
-----	---

G03D	PROGESTOGENS <ul style="list-style-type: none">➤ Flumedroxone is classified in N02C
------	--

G3D	PROGESTOGENS, EXCLUDING G3A,G3F <ul style="list-style-type: none">➤ Flumedroxone is classified here
-----	---

WHO (Substance based)

EphMRA (Product based)

G03E	ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION	G3E	ANDROGEN WITH FEMALE HORMONE COMBINATIONS
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION ➤ Estradiol and cyproterone in combination is classified in G03H B	G3F	OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A ➤ Estradiol and cyproterone in combination is classified here
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	G3G	GONADOTROPHINS, INCL.OTHER OVULATION STIMULANTS
G03H	ANTIANDROGENS ➤ All plain cyproterone preparations and combinations of cyproterone and estrogen regardless of indication	❖	
❖	➤ Bazedoxifene, lasofoxifene and raloxifene are classified in G03X	G3J	SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS) ➤ Bazedoxifene, lasofoxifene and raloxifene are classified here
G03X	OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ➤ Tibolone is classified in G03DC ➤ Bazedoxifene, lasofoxifen and raloxifene are classified here ➤	G03X	OTHER SEX HORMONES AND SIMILAR PRODUCTS ➤ Tibolone is classified here ➤ Products containing cyproterone are classified according to indication ➤ Combinations of estrogen and cyproterone are classified in D10B (DIANE 35) and G3F (CLIMEN) ➤ Bazedoxifene, lasofoxifen and raloxifene are classified in G3J

WHO (Substance based)

EphMRA (Product based)

G04 UROLOGICALS		G4 UROLOGICALS	
❖	<ul style="list-style-type: none"> ➤ Urinary quinolones are in J01M ➤ Other urinary antibacterials are in J01X 	G4A	URINARY ANTI-INFECTIVES AND ANTISEPTICS <ul style="list-style-type: none"> ➤ Urinary quinolones are here in G4A2 ➤ Halogenated quinolones are in G4E ➤ Other antiseptics and anti-bacterials are here in G4A9
G04B	OTHER UROLOGICALS, INCL. ANTISPASMODICS <ul style="list-style-type: none"> ➤ Drugs used in erectile dysfunction are here in G04B E ➤ Urinary antispasmodics are here in G04B D 	❖	<ul style="list-style-type: none"> ➤ Other urologicals are in G4X with exceptions below ➤ Erectile dysfunction products are in G4E ➤ Urinary incontinence products are in G4D
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	G4C	BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS
❖		G4D	URINARY INCONTINENCE PRODUCTS
❖	<ul style="list-style-type: none"> ➤ Phentolamine used as an antidote is in V03A. It is only in G04B for erectile dysfunction when in combinations. 	G4E	ERECTILE DYSFUNCTION PRODUCTS <ul style="list-style-type: none"> ➤ Phentolamine for erectile dysfunction is here. It is in V3X when used as an antidote
❖	<ul style="list-style-type: none"> ➤ Other urologicals are in G04B 	G4X	ALL OTHER UROLOGICAL PRODUCTS

WHO (Substance based)

EphMRA (Product based)

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES

H SYSTEMIC HORMONAL PREPARATIONS (EXCL. SEX HORMONES)

The classification of these hormonal products is based according to the origin of the hormones and not according to their indication

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

H1 PITUITARY AND HYPOTHALAMIC HORMONES



H01A ANTERIOR PITUITARY LOBE HORMONES and ANALOGUES

H1A ACTH

H01A A ACTH

Included in H3A THYROID PREPARATIONS

H01A B Thyrotrophin

H4C

GROWTH HORMONES

H01A C Somatropin and somatropin agonists



H01A X Other anterior pituitary lobe hormones and analogues

➤ Pegvisomant is classified here

Pegvisomant is classified in H1C

H01B POSTERIOR PITUITARY LOBE HORMONES



H01B A Vasopressin and analogues

H4D ANTIDIURETIC HORMONES

➤ Terlipressin is classified here

➤ Terlipressin is classified in B2G

H01B B Oxytocin and analogues

G2A LABOUR INDUCERS

H01C HYPOTHALAMIC HORMONES

H1C HYPOTHALAMIC HORMONES

H01C A GONADOTROPHIN-RELEASING HORMONES

H1C1 GONADOTROPHIN RELEASING HORMONES

WHO (Substance based)

EphMRA (Product based)

H01C B ANTIGROWTH HORMONES

H1C2 ANTIGROWTH HORMONES

H01C C ANTI-GONADOTROPHIN-RELEASING HORMONES

H1C3 ANTIGONADOTROPHIN-RELEASING HORMONES

H02 CORTICOSTEROIDS FOR SYSTEMIC USE

H2 SYSTEMIC CORTICOSTEROIDS

H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

H2A SYSTEMIC CORTICOSTEROIDS, PLAIN

H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS

H2B SYSTEMIC CORTICOSTEROID COMBINATIONS

H02C ANTIADRENAL PREPARATIONS

❖

➤ Trilostane is classified here

➤ Trilostane is classified in H4X

H03 THYROID THERAPY

H3 THYROID THERAPY

H03A THYROID PREPARATIONS

H3A THYROID PREPARATIONS

➤ Thyrotrophin is classified in H01A

➤ Thyrotrophin is classified here

H03B ANTITHYROID PREPARATIONS

H3B ANTI-THYROID PREPARATIONS

H03C IODINE THERAPY

H3C IODINE THERAPY

H04 PANCREATIC HORMONES

❖



H04A GLYCOGENOLYTIC HORMONES

H4B GLUCAGON

H05 CALCIUM HOMEOSTASIS

❖

H05A PARATHYROID HORMONES AND ANALOGUES

H4E PARATHYROID HORMONES AND ANALOGUES

H05B ANTI-PARATHYROID HORMONES

H4A CALCITONINS

WHO (Substance based)

EphMRA (Product based)

H05B A Calcitonin preparations

H05B X Other anti-parathyroid agents

➤ Cinacalcet and paricalcitol are classified in A11C2

WHO (Substance based)

EphMRA (Product based)

J ANTIINFECTIVES FOR SYSTEMIC USE

J01 ANTIBACTERIALS FOR SYSTEMIC USE

J01A TETRACYCLINES

➤ Tigecycline is classified here

J01B AMPHENICOLS

J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS

J01D OTHER BETA LACTAM ANTIBACTERIALS

J01D B-E ➤ First-fourth generation cephalosporins

➤ Loracarbef is classified here in J01D C

I ➤ Other cephalosporins

J01D F Monobactams

J01D H Carbapenems

J01E SULFONAMIDES AND TRIMETHOPRIM

J GENERAL ANTI-INFECTIVES SYSTEMIC

J1 SYSTEMIC ANTIBACTERIALS

J1A TETRACYCLINES AND COMBINATIONS

➤ Tigecycline is classified in J1X

J1B CHLORAMPHENICOL AND COMBINATIONS

J1C BROAD SPECTRUM PENICILLINS

+

J1H MEDIUM AND NARROW SPECTRUM PENICILLINS

+

J1L CARBENICILLIN AND SIMILAR TYPES

❖

J1D CEPHALOSPORINS

J1D1-2 ➤ Oral – injectable cephalosporins

➤ Loracarbef is classified in J1P3

J1P1 Monobactams

J1P2 Carbapenems

J1E TRIMETHOPRIM AND SIMILAR FORMULATIONS

+

WHO (Substance based)

EphMRA (Product based)

		J3A	SYSTEMIC SULFONAMIDES
J01F	MACROLIDES, LINCOSAMIDES and STREPTOGRAMINS ➤ Pristinamycin is classified here	J1F	MACROLIDES AND SIMILAR TYPES ➤ Pristinamycin is classified in J1X
J01G	AMINOGLYCOSIDE ANTIBACTERIALS ➤ Plain streptomycin is classified here	J1K	AMINOGLYCOSIDES ➤ Streptomycin is classified in J1X
J01M	QUINOLONE ANTIBACTERIALS	J1G	FLUOROQUINOLONES ➤ Non-halogenated quinolones are in G4A2
J01R	COMBINATIONS OF ANTIBACTERIALS Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified here.	❖	Sulfonamides in combinations with other antibacterials (excl. trimethoprim) are classified in J3A.
❖	➤ Monobactams, carbapenems, carbacephems are classified in J01D	J1P	OTHER BETA-LACTAM ANTIBACTERIALS, EXCLUDING PENICILLINS, CEPHALOSPORINS ➤ Monobactams, carbapenems, carbacephems are classified here
J01X	OTHER ANTIBACTERIALS Pristinamycin is classified J01F ; Tigecyclin is in J01A Parenteral imidazole formulations are classified here in J01XD	J1X	OTHER ANTIBACTERIALS Pristinamycin, tigecyclin are classified here Parenteral imidazole formulations are classified in J8B
J02	ANTIMYCOTICS FOR SYSTEMIC USE Terbinafine and griseofulvin are classified in D01B	J2	SYSTEMIC AGENTS FOR FUNGAL INFECTIONS Terbinafine for systemic use is classified here Griseofulvin is classified in D1A2

WHO (Substance based)

EphMRA (Product based)

❖		J3	SYSTEMIC SULPHONAMIDES
	All plain sulphonamides are classified in J01E. Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified in J01R.		This group includes plain sulphonamides and sulphonamide/antibiotic combinations, excl trimethoprim/sulphonamides which are classified J1E.
❖		J3	SYSTEMIC SULPHONAMIDES
J04	ANTIMYCOBACTERIALS	J4	ANTIMYCOBACTERIALS
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS	J4A	ANTITUBERCULAR PRODUCTS
	➤ Rifampicin and rifamycin are classified here		➤ Rifampicin and rifamycin are classified here and in J1M
	➤ Plain streptomycin is classified in J01G A		➤ Streptomycin is classified here
J04B	DRUGS FOR TREATMENT OF LEPROSY	J4B	DRUGS FOR THE TREATMENT OF LEPROSY
	Thalidomide, also when used for leprosy, is classified L04AX		Thalidomide, when used for leprosy is classified here
J05	ANTIVIRALS FOR SYSTEMIC USE	J5	ANTIVIRALS FOR SYSTEMIC USE
J05A	Direct acting antivirals	J5B	➤ ANTIVIRALS, excl. ANTI-HIV PRODUCTS
	The combination of ribavirin and peginterferon is classified L03A		The combination of ribavirin and peginterferon is classified here.
		+	
		J5C	HIV ANTIVIRALS
	Antivirals acting against HIV are classified here in J05AE – J05AG depending on inhibition mechanism		HIV antivirals are classified here in J5C1 – J5C9 depending on inhibition mechanism
J06	IMMUNE SERA AND IMMUNOGLOBULINS	J6	SERA AND GAMMA-GLOBULIN

WHO (Substance based)

EphMRA (Product based)

J06A IMMUNE SERA

J6A ANTITOXIC SERA

J06B IMMUNOGLOBULINS

J6C POLYVALENT IMMUNO-GLOBULINS - INTRAVENOUS

+

J6D HOMOLOGOUS IMMUNOLOGICALLY ACTIVE GLOBULINS - INTRAVENOUS

+

J6E POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR

+

J6F POLYVALENT IMMUNO-GLOBULINS – COMBINATION MODULATION - MAINLY INTRAMUSCULAR

+

J6G SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL

+

J6H SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL

+

J6J OTHER SPECIFIC IMMUNOGLOBULINS

J07 VACCINES

J7 VACCINES

J07A BACTERIAL VACCINES

J7A PURE VACCINES

Also combinations of bacterial vaccines

All vaccines that act against a specific group of virus or bacteria are classified here. All combinations acting against more than one group of virus or bacteria are classified in J7B

WHO (Substance based)

EphMRA (Product based)

J07B	VIRAL VACCINES		
	Also combinations of viral vaccines		Viral vaccines are classified in J7A if acting against a specific group of virus. Combinations are classified in J7B
J07C	BACTERIAL AND VIRAL VACCINES, COMBINED	J7B	COMBINATIONS OF VACCINES
	Bacterial vaccines combinations and viral vaccines combination are classified J07A and J07B respectively.		All combinations of bacterial and viral vaccines are classified here
J07X	OTHER VACCINES	J7C	ALL OTHER VACCINES
❖		J8	OTHER ANTI-INFECTIVES
	Parenteral imidazole formulations are classified in J01XD		Parenteral imidazole formulations are classified here in J8B

WHO (Substance based)

EphMRA (Product based)

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L01 ANTINEOPLASTIC AGENTS

L01A ALKYLATING AGENTS

➤ Altretamine is classified in L01X

L01B ANTIMETABOLITES

➤ Methotrexate is classified in L01B and L04A

L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

➤ Gemtuzumab ozogamicin is classified in L1X.

L01X OTHER ANTINEOPLASTIC AGENTS

➤ Altretamine is classified here

➤ Aminolevulinic acid is classified here

➤ Alitretinoin is classified in D11A

L01X A Platinum compounds

L01X B Methylhydrazines

L01X C Monoclonal Antibodies

➤ Gemtuzumab ozogamicin is classified here.

L01X D Agents used in photodynamic therapy

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L1 CYTOSTATICS

L1A ALKYLATING AGENTS

➤ Altretamine is classified here

L1B ANTIMETABOLITES

➤ Methotrexate is classified in D5B, M1C and L01B

L1C VINCA ALKALOIDS AND OTHER PLANT PRODUCTS

L1D CYTOSTATIC ANTINEOPLASTICS

➤ Gemtuzumab ozogamicin is classified here.

L1X ALL OTHER ANTINEOPLASTICS

➤ Altretamine is classified in L1A

➤ Aminolevulinic acid is classified in D5X

L1X2 Platinum compounds

L1X9

L1X3 Antineoplastic Monoclonal Antibodies

➤ Gemtuzumab ozogamicin is classified in L1D.

L1X9

WHO (Substance based)

EphMRA (Product based)

L01X E Protein kinase inhibitors
L01X X Other antineoplastic agents

L1X4 Antineoplastic protein kinase inhibitors
L1X1 Adjuvants preparations for cancer therapy
+ ➤ Alitretinoin is classified here when indicated to treat cutaneous lesions in Kaposi's sarcoma and in D5X when indicated for the treatment of eczema
L1X9 All other antineoplastics

L02 ENDOCRINE THERAPY

L02A HORMONES AND RELATED AGENTS
L02A A Estrogens
L02A B Progestogens
L02A E Gonadotrophin releasing hormone analogues
L02A X Other Hormones

L2 CYTOSTATIC HORMONE THERAPY

L2A CYTOSTATIC HORMONES
L2A1 Cytostatic oestrogens
L2A2 Cytostatic progestogens
L2A3 Cytostatic gonadotrophin releasing hormone analogues
L2A9 Other cytostatic hormones

L02B HORMONE ANTAGONISTS AND RELATED AGENTS

L02B A Anti-estrogens
L02B B Anti-androgens
L02B G Enzyme inhibitors
❖ Fulvestrant is classified in L2B A

L2B CYTOSTATIC HORMONE ANTAGONISTS

L2B1 Cytostatic anti-estrogens
L2B1 Cytostatic anti-androgens
L2B3 Cytostatic aromatase inhibitors
L2B9 Other cytostatic hormone antagonists

L03 IMMUNOSTIMULANTS

L03A CYTOKINES AND IMMUNOMODULATORS

L3 IMMUNOMODULATING AGENTS

L3A IMMUNOSTIMULATING AGENTS, EXCL. INTERFERONS
➤ Levamisole, when indicated as immunostimulant, is classified

WHO (Substance based)

- Levamisole is classified in PO2CE
- Melanoma vaccine is classified here

L03A A Colony stimulating factors

L03A C + Interleukins +

L03A X Other cytokines and immunomodulators

L03A B INTERFERONS

EphMRA (Product based)

here

- Melanoma vaccine is classified in J7C

L3A1 COLONY STIMULATING FACTORS

L3A9 All other immunostimulating agents excluding interferons

L3B INTERFERONS

- Interferons indicated for viral hepatitis only are classified in J5B

L04 IMMUNOSUPPRESSANTS

L04A IMMUNOSUPPRESSANTS

- Alefacept is classified here
- Abatacept, anakinra, leflunomide and tocilizumab are classified here
- Methotrexate is classified in L01B and L04A
- **Ustekinumab is classified here**



L4 IMMUNOSUPPRESSIVE AGENTS

+ These are split between L4B for anti-TNFs and L4X for other immunosuppressants.

- Alefacept is classified in D5B
- Anakinra abatacept, leflunomide and tocilizumab are classified in M1C
- Methotrexate is classified in D5B, M1C and L01B
- **Ustekinumab is classified in D5B**

L4B ANTI-TNF PRODUCTS

L4X OTHER IMMUNOSUPPRESSANTS

WHO (Substance based)

EphMRA (Product based)

M	MUSCULO-SKELETAL SYSTEM	M	MUSCULO-SKELETAL SYSTEM
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	M1	ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS
M01A	ANTIINFLAMMATORY and ANTIRHEUMATIC PRODUCTS, NON STEROIDS <ul style="list-style-type: none">➤ This group comprises antiinflammatory preparations for systemic use, regardless of strength➤ Mefenamic acid is classified here➤ Ketorolac is classified here➤ Chondroitin, Diacerein and Glucosamine are classified here	M1A	ANTI-RHEUMATIC, NON STEROIDAL <ul style="list-style-type: none">➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M1A. Those that are indicated mainly for general pains are in N2B.➤ Mefenamic acid is classified in N2B➤ Ketorolac is classified in N2B➤ Chondroitin, Diacerein and Glucosamine are classified in M5X
M01B	ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION		
M01B A	Antiinflammatory/antirheumatic agents in combination with corticosteroids	M1B	ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS
M01C	SPECIFIC ANTIRHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified in P01B➤ Anakinra, abatacept, leflunomide and tocilizumab are classified in L4A➤ Methotrexate is classified in L01B and L04A	M1C	SPECIFIC ANTI-RHEUMATIC AGENTS <ul style="list-style-type: none">➤ Chloroquine is classified here and in P1D➤ Anakinra, abatacept, leflunomide and tocilizumab are classified here➤ Methotrexate is classified in D5B, M1C and L01B
M02	TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	M2	TOPICAL ANTI-RHEUMATICS AND ANALGESICS

WHO (Substance based)

EphMRA (Product based)

M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

- Bendazac is classified here
- Bufexamac is classified here

M2A TOPICAL ANTI-RHEUMATICS AND ANALGESICS

- Bendazac is classified in D3A
- Bufexamac is also classified in D4A
- Nimesulide in throat preparations is also classified in R2A

M03 MUSCLE RELAXANTS

M3 MUSCLE RELAXANTS

M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS

- Dantrolene is classified in M03C

M3A MUSCLE RELAXANTS, PERIPHERALLY ACTING

- Dantrolene is classified here

M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS

M3B MUSCLE RELAXANTS, CENTRALLY ACTING

M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS

- Dantrolene is classified here

❖

- Dantrolene is classified in M3A

M04 ANTI-GOUT PREPARATIONS

M4 ANTI-GOUT PREPARATIONS

M04A ANTI-GOUT PREPARATIONS

M4A ANTI-GOUT PREPARATIONS

M5 DRUGS FOR TREATMENT OF BONE DISEASES

M5 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION

M5B BONE CALCIUM REGULATORS



- Eptotermin alfa is classified here
- Dibotermin alfa is classified here

- Eptotermin alfa is classified in M5X
- Dibotermin alfa is classified in M5X

M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

❖

WHO (Substance based)

EphMRA (Product based)

M09A A Quinine and DERIVATES

+

M09A X Other drugs for disorders of the Musculo-skeletal system

➤ Eptotermin alfa is classified in M5B

➤ Dibotermin alfa is classified in M5B

M09A B Enzymes

Included in
M5X

ALL OTHER MUSCULOSKELETAL PRODUCTS

➤ Eptotermin alfa is classified here

➤ Dibotermin alfa is classified here

V3H

ANTI INFLAMMATORY ENZYMES

WHO (Substance based)

EphMRA (Product based)

N	NERVOUS SYSTEM	N	CENTRAL NERVOUS SYSTEM
N01	ANESTHETICS	N1	ANAESTHETICS
N01A	ANESTHETICS, GENERAL	N1A	ANAESTHETICS, GENERAL
	➤ Fentanyl in combination with droperidol is classified here		➤ Phenoperidine, anileridine and fentanyl in combination with droperidol are classified in N2A
N01B	ANESTHETICS, LOCAL	N1B	ANAESTHETIC LOCAL
	➤ Capsicum for neuropathic pain is classified here, otherwise it is in M02A		➤ Topical capsicum is classified in M2A or, when used for neuropathic pain, in N7X.
N02	ANALGESICS	N2	ANALGESICS
↻	➤ All antiinflammatory products are classified in M01A, regardless of strength		➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M01A. Those that are indicated mainly for general pains are in N2B.
	➤ Analgesic/cold preparations are classified here intended for use as pain relief		➤ Analgesic/cold preparations are classified in R5A
	➤ Analgesics indicated for dysmenorrhea are classified here		➤ Products specifically indicated for dysmenorrhea are classified in G2X1
N02A	OPIOIDS	N2A	NARCOTICS
↻	➤ This classification is based solely on substances, not on legal status		➤ Includes all analgesics classified as narcotics in accordance with the <u>legal definition of narcotic analgesics in each country</u>
	➤ Dihydrocodeine is classified here		➤ Dihydrocodeine is classified in N2B
N02B	OTHER ANALGESICS AND ANTIPYRETICS	N2B	NON-NARCOTICS AND ANTI-PYRETICS
↻	➤ Nabiximols (cannabidiol and tetrahydrocannabinol) is		➤ Nabiximols (cannabidiol and tetrahydrocannabinol), used for

WHO (Substance based)

EphMRA (Product based)

classified here

refractory spasticity, is classified in N7X

WHO (Substance based)

EphMRA (Product based)

-
- N02C** **ANTIMIGRAINE PREPARATIONS**
- Dihydroergotamine which is also used in the treatment of hypotension, is classified in this group
 - Pizotifen is classified here
 - Lisuride (low dose) is classified here and in G02C (high dose)
 - Flumedroxone is classified here

- N2C** **ANTI MIGRAINE PREPARATIONS**
- Dihydroergotamine is classified here and also in C1C1
 - Pizotifen is classified here and in A15
 - Lisuride is classified in N4A
 - Flumedroxone is classified in G3D

N03 **ANTIEPILEPTICS**

N3 **ANTI-EPILEPTICS**

N03A **ANTIEPILEPTICS**

N3A **ANTI-EPILEPTICS**

N04 **ANTI-PARKINSON DRUGS**

N4 **ANTI-PARKINSON DRUGS**

- Lisuride is classified in N02C and in G02C

- Lisuride is classified here
-

WHO (Substance based)

EphMRA (Product based)

N05 PSYCHOLEPTICS

The group is divided into therapeutic subgroups:

N05A – Antipsychotics

➡ N05B – Anxiolytics

➡ N05C – Hypnotics and sedatives

N5 PSYCHOLEPTICS

The group is divided into therapeutic subgroups:

N5A – Antipsychotics

➡ N5B – Hypnotic/Sedatives

➡ N5C – Tranquilizers

N05A ANTIPSYCHOTICS

- Lithium is classified here
- Butaperazine is classified here

N5A ANTIPSYCHOTICS

- Lithium is classified in N6A
- Butaperazine is classified in A4A

N05B ANXIOLYTICS

- Mebutamate is classified here
- Mefenoxalone is classified here

N5C TRANQUILLISERS

- Mebutamate is classified in C2A
- Metenoxalone is classified in M3B

N05C HYPNOTICS AND SEDATIVES

- Melatonin is classified here

N5B HYPNOTICS / SEDATIVES

- Melatonin (plain) indicated for sleep rhythm disturbances is classified in H4X. Prolonged-release melatonin indicated for primary insomnia is classified here.

N06 PSYCHOANALEPTICS

N6 PSYCHOANALEPTICS EXCL. ANTI-OBESITY PREPARATIONS

N06A ANTIDEPRESSANTS

N06A ANTI-DEPRESSANTS AND MOOD STABILISERS

WHO (Substance based)

EphMRA (Product based)

- Lithium is classified in N05A
- Ademetionine is in A16A
- Bupropion is classified here

- Lithium is classified here
- Ademetionine is classified here
- Bupropion is classified here and in N7B

N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND
NOOTROPICS

- Dexamfetamine and metamfetamine are classified here
- Caffeine is classified here
- Citicoline is classified here
- Atomoxetine is classified here

N6B PSYCHOSTIMULANTS

- Dexamfetamine and metamfetamine are classified here and in A8
- Plain caffeine is classified in C1C1
- Citicoline is classified in C4A
- Atomoxetine is classified in N7X

+
N6D NOOTROPICS

+
N6E NEUROTONICS AND OTHER MISCELLANEOUS PRODUCTS

N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN
COMBINATION

N6C PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS

N06D ANTI-DEMENTIA DRUGS

N7D Anti-Alzheimer Products

N07 OTHER NERVOUS SYSTEM DRUG

N7 OTHER CNS DRUGS



WHO (Substance based)

EphMRA (Product based)

N07A	PARASYMPATHOMIMETICS	❖	OTHER CNS DRUGS
	<ul style="list-style-type: none">➤ Nalorphine, naltrexone, naloxone and flumazenil are classified in V03A➤ Cevimeline is classified here	Included in N7X	<ul style="list-style-type: none">➤ Nalorphine, naltrexone, naloxone and flumazenil are classified in N7X.➤ Cevimeline is classified in A01A
N07B	DRUGS USED IN ADDICTIVE DISORDERS		
N07B A	Drugs used in nicotine dependence	N7B	ANTISMOKING PRODUCTS
	<ul style="list-style-type: none">➤ Bupropion is classified in N6A		<ul style="list-style-type: none">➤ Bupropion is classified here and N6A (antidepressant)
N07B B	Drugs used in alcohol dependence	N7E	DRUGS USED IN ALCOHOL DEPENDENCE
N07B C	Drugs used in opioid dependence	N7F	DRUGS USED IN OPIOID DEPENDENCE
N07C	ANTIVERTIGO PREPARATIONS	N7C	ANTIVERTIGO PREPARATIONS
N07X	OTHER NERVOUS SYSTEM DRUGS	N7X	<i>ALL OTHER CNS DRUGS</i>
↻	<ul style="list-style-type: none">➤ Sugammadex is classified in V03AB here➤ Topical capsicum, when used for neuropathic pain, is classified in N01B➤ Nabiximols (cannabidiol and tetrahydrocannabinol) is classified in N02B		<ul style="list-style-type: none">➤ Sugammadex is classified here➤ Topical capsicum, when used for neuropathic pain, is classified here.➤ Nabiximols (cannabidiol and tetrahydrocannabinol) is classified here

WHO (Substance based)

EphMRA (Product based)

P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

This group is subdivided according to types of parasites

P01 ANTIPROTOZOALS



P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

- Systemic metronidazole is classified here and in J01XD
- Clioquinol, chlorquinaldol, tilbroquinol and glycobriarsol are classified here

P01B ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here

P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS



P02 ANTHELMINTICS



The anthelmintics are subdivided according to the main type of worms (i.e. trematodes, nematodes and cestodes) causing the

P PARASITOLOGY

P1 ANTI-PARASITIC PRODUCTS



P1A AMOEBICIDES

- Nitroimidazole derivatives are classified either in G1A or J8B
- Clioquinol, chlorquinaldol, tribroquinol and glycobriarsol are classified in A7A

P1D ANTI-MALARIALS

- Chloroquine and hydroxychloroquine are classified here and in M1C

P1G OTHER ANTI-PARASITIC AGENTS

P1C SCHISTOSOMICIDES



+

P1B ANTHELMINTICS, EXCL. SCHISTOSOMICIDES

WHO (Substance based)

EphMRA (Product based)

infections

➤ Levamisole is classified here

➤ Levamisole is classified here in L3A

P03 **ECTOPARASITICIDES, INCL. SCABICIDES,
INSECTISIDES AND REPELLENTS**

P3 **ECTOPARASITICIDES, INCL. SCABICIDES, INSECTISIDES
AND REPELLENTS**

P03A ECTOPARASITICIDES, INCL. SCABICIDES

P3A ECTOPARASITICIDES, incl. SCABICIDES

P03B INSECTICIDES AND REPELLENTS

P3B INSECTICIDES AND REPELLENTS

➤ Dimethylphthalate is classified here

➤ Dimethylphthalate is classified in D4A

WHO (Substance based)

EphMRA (Product based)

R **RESPIRATORY SYSTEM****R01** **NASAL PREPARATIONS**

R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS
FOR TOPICAL USE

R01B NASAL DECONGESTANTS FOR SYSTEMIC USE

R02 **THROAT PREPARATIONS**

R02A THROAT PREPARATIONS

- Preparations for the treatment of throat infections (lozenges for common cold condition) are classified here

R03 **DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES**

This group is harmonized on the second level

- Azelastine is classified in R06
- Ketotifen is classified in R06A
- Terfenadine is classified in R06A

**R** **RESPIRATORY SYSTEM****R1** **NASAL PREPARATIONS**

R01A TOPICAL NASAL PREPARATIONS

R1B SYSTEMIC NASAL PREPARATIONS

R2 **THROAT PREPARATIONS**

R2A THROAT PREPARATIONS

- Products indicated for both the posterior part of the mouth and throat infections are classified in R2A or A1A depending on the main indication
- Nimesulide in throat preparations is also here

R3 **ANTI-ASTHMA AND COPD PRODUCTS**

- Azelastine is classified here
- Ketotifen is classified here
- Terfenadine (Japan only) is classified here, in all other countries in R6A

R4 **CHEST RUBS AND OTHER INHALANTS**

WHO (Substance based)

EphMRA (Product based)

R05	COUGH AND COLD PREPARATIONS	R5	COUGH AND COLD PREPARATIONS
➡	<ul style="list-style-type: none">➤ Cold preparations with therapeutic levels of antiinfectives should be classified in ATC group J – Antiinfectives for systemic use➤ Cold preparations with therapeutic levels of analgesics/antiinflammatory agents should be classified in the respective N02/M01 groups		<ul style="list-style-type: none">➤ COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES (R5B)➤ COLD PREPARATIONS WITHOUT ANTI-INFECTIVES (R5A)
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	R5C	EXPECTORANTS
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	R5D	ANTITUSSIVES
	<ul style="list-style-type: none">➤ Cough suppressants with expectorants are in R05F		<ul style="list-style-type: none">➤ Cough suppressants combination preparations are here in R5D2
+			
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	R5F	OTHER COUGH AND COLD PREPARATIONS
			<ul style="list-style-type: none">➤ This group includes combinations without clearly expectorating or antitussive effect, expectorant teas and lozenges / medical sweets for cough.
R05X	OTHER COLD COMBINATION PREPARATIONS	❖	
R06	ANTIHISTAMINES FOR SYSTEMIC USE	R6	SYSTEMIC ANTIHISTAMINES
R06A	ANTIHISTAMINES FOR SYSTEMIC USE	R6A	SYSTEMIC ANTIHISTAMINES
	<ul style="list-style-type: none">➤ Antihistamines for systemic use are classified here➤ Cyproheptadine is classified here		<ul style="list-style-type: none">➤ Antihistamines used in motion sickness are classified in A4A➤ Cyproheptadine is also classified in A15

WHO (Substance based)

- Thiethylperazine is classified here
- Azelastine and ketotifen are classified here

EphMRA (Product based)

- Thiethylperazine is classified in A4A
- Azelastine and ketotifen are classified in R3C

R07 OTHER RESPIRATORY SYSTEM PRODUCTS

R07A OTHER RESPIRATORY SYSTEM PRODUCTS

R07A A LUNG SURFACTANTS

R07A B RESPIRATORY STIMULANTS

R07A X OTHER RESPIRATORY SYSTEM PRODUCTS

R7 OTHER RESPIRATORY SYSTEM PRODUCTS

R7C LUNG SURFACTANTS

R7A RESPIRATORY STIMULANTS

R7X ALL OTHER RESPIRATORY SYSTEM PRODUCTS

WHO (Substance based)

EphMRA (Product based)

S	SENSORY ORGANS	S	SENSORY ORGANS
S01	OPHTHALMOLOGICALS	S1	OPHTHALMOLOGICALS
S01A	ANTIINFECTIVES	S1A	OPHTHALMOLOGICAL ANTI-INFECTIVES
S01A D	Antivirals	+	
		S1D	OPHTHALMOLOGICAL ANTIVIRAL AGENTS
S01B	ANTIINFLAMMATORY AGENTS	S1B	OPHTHALMOLOGICAL CORTICOSTEROIDS
S01B C	Antiinflammatory agents, non-steroids	+	
		S1R	OPHTHALMIC NONSTEROIDAL ANTIINFLAMMATORIES
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	S1C	OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTIINFECTIVE COMBINATIONS
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS	S1E	MIOTICS AND ANTIGLAUCOMA PREPARATIONS
S01F	MYDRIATICS AND CYCLOPLEGICS	S1F	MYDRIATICS AND CYCLOPLEGICS
S01G	DECONGESTANTS AND ANTIALLERGICS	S1G	OCULAR ANTI-ALLERGICS, DECONGESTANTS, ANTISEPTICS
S01H	LOCAL ANESTHETICS	S1H	OPHTHALMOLOGICAL LOCAL ANESTHETICS
S01J	DIAGNOSTIC AGENTS	S1T	OPHTHALMOLOGICAL DIAGNOSTIC AGENTS
S01K	SURGICAL AIDS	S1S	OPHTHALMOLOGICAL SURGICAL AIDS
S1L	ANTINEOVASCULARISATION AGENTS	S1P	OCULAR ANTINEOVASCULARISATION PRODUCTS
			➤ Verteporfin, rostoporfin, pegaptanib are classified here.
❖		S1K	ARTIFICIAL TEARS AND OCULAR LUBRICANTS

WHO (Substance based)**EphMRA (Product based)**

❖		S1L	PREPARATIONS FOR USE WITH CONTACT LENSES
❖		S1M	EYE TONICS and EYE VITAMINS
❖		S1N	PREPARATIONS TO PREVENT CATARACT AND ANTICATARACTOGENICS
<hr/>			
S01X	OTHER OPHTHALMOLOGICALS	S1X	OTHER OPHTHALMOLOGICALS
<hr/>			
S02	OTOLOGICALS	S2	OTOLOGICALS
S02A	ANTIINFECTIVES	S2A	OTIC ANTI-INFECTIVES
S02B	CORTICOSTEROIDS	S2B	OTIC CORTICOSTEROIDS
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	S2C	OTIC CORTICOSTEROID/ANTIINFECTIVE COMBINATIONS
S02D	OTHER OTOLOGICALS	S2D	OTHER OTOLOGICALS
<hr/>			
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	S3	OPHTHALMOLOGICAL/OTOLOGICAL COMBINATIONS
S03A	ANTIINFECTIVES	S3A	EYE/EAR ANTI-INFECTIVES
S03B	CORTICOSTEROIDS	S3B	EYE/EAR CORTICOSTEROIDS
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMB.	S3C	EYE/EAR CORTICOSTEROID/ANTI-INFECTIVE COMBI.

WHO (Substance based)

EphMRA (Product based)

S03D OTHER OPHTHALMOLOGICAL AND OTOLOGICAL
PREPARATIONS

S3D OTHER EYE/EAR COMBINATIONS

WHO (Substance based)

EphMRA (Product based)

V	VARIOUS	V	VARIOUS
V01	ALLERGENS	V1	ALLERGENS
V01A	ALLERGENS	V1A	ALLERGENS
V03	ALL OTHER THERAPEUTIC PRODUCTS	V3	ALL OTHER THERAPEUTIC PRODUCTS
V03A	ALL OTHER THERAPEUTIC PRODUCTS	V3A	❖
V03A B	ANTIDOTES <ul style="list-style-type: none">➤ Zinc acetate is classified in A16A➤ Sugammadex is classified here➤ Plain phentolamine as an antidote is classified here	V3E	ANTIDOTES <ul style="list-style-type: none">➤ Zinc acetate is classified here when indicated for Wilson's disease➤ Sugammadex is classified in N7X➤ Phentolamine for ED is in G4E➤ Phentolamine when used as an antidote is classified in V3X
V03A C	IRON CHELATING AGENTS	V3F	IRON-CHELATING AGENTS
V03A E	DRUGS FOR THE TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA	V3G	HYPERKALAEMIA/HYPERPHOSPHATEMIA PRODUCTS
V03A F	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT	V3D	DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03A G – V03A Z	<ul style="list-style-type: none">➤ Nalfurafine is classified in V03A X➤ Phentolamine when used as an antidote/reversal agent is classified in V03AB	V3X	ALL OTHER THERAPEUTIC PRODUCTS <ul style="list-style-type: none">➤ Nalfurafine is classified in D4A➤ Phentolamine when used as an antidote is classified here
V04	DIAGNOSTIC AGENTS	❖	
		T	DIAGNOSTIC AGENTS

WHO (Substance based)

EphMRA (Product based)

V04B	URINE TESTS	T2C	PREGNANCY AND OVULATION TESTS
		T2D1	Diabetes tests, urine
		T2X1	All other diagnostic tests, urine
V04C	OTHER DIAGNOSTIC AGENTS	T2X2 +	All other diagnostic tests, blood
		T2X9	All other diagnostic tests
V04C A	Tests for diabetes	T2D2 +	Diabetes tests, blood
		T2D9	Diabetes tests, other
❖		T3	DIAGNOSTIC EQUIPMENT AND ACCESSORIES
V6	GENERAL NUTRIENTS	V6	DIETETIC AGENTS
V6A	DIET FORMULATIONS FOR TREATMENT OF OBESITY	V6A	SLIMMING PREPARATIONS
V6B	PROTEIN SUPPLEMENTS	V6B	PROTEIN SUPPLEMENTS
V6C	INFANT FORMULAS	V6C	INFANT FORMULAS
V6D	OTHER NUTRIENTS	V6D	OTHER NUTRIENTS
V7	ALL OTHER NON-THERAPEUTIC PRODUCTS	V7	ALL OTHER NON-THERAPEUTIC PRODUCTS
V7A	ALL OTHER NON-THERAPEUTIC PRODUCTS	V7A	ALL OTHER NON-THERAPEUTIC PRODUCTS
V8	CONTRAST MEDIA	❖	Classified in group T
V8A	X-RAY CONTRAST MEDIA, IODINATED	T1A +	LOW OSMOLAR ANGIO-UROGRAPHY
		T1B +	IONIC ANGIO-UROGRAPHY

WHO (Substance based)

EphMRA (Product based)

V8B	X.RAY CONTRAST MEDIA, NON-IODINATED	T1D	CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY
V8C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA	T1C	GASTROENTEROGRAPHY
V8D	ULTRASOUND CONTRAST MEDIA	T1E	MRI AGENTS
		❖	
		T1F	ULTRASOUND AGENTS
		T1X	OTHER IMAGING AGENTS

V9	DIAGNOSTIC RADIOPHARMACEUTICALS	❖	Classified in group T
		T1G	RADIODIAGNOSTIC AGENTS

V10	THERAPEUTIC RADIOPHARMACEUTICALS	V3C	RADIOPHARMACEUTICALS
------------	---	-----	----------------------

V20	SURGICAL DRESSINGS	❖	
------------	---------------------------	---	--
